Application of PLGA-PEG-PLGA Nanoparticles to Percutaneous Immunotherapy for Food Allergy
Molecules · 30.08.2024 · 29 (17) · 4123
DOI: 10.3390/molecules29174123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 30.08.2024. Verfasst von Ryuse Sakurai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641, Yamazaki, Noda 278-8510, Chiba, Japan. Hauptthemen laut MEDLINE: Nanoparticles, Polyethylene Glycols, Food Hypersensitivity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Compared with oral or injection administration, percutaneous immunotherapy presents a promising treatment modality for food allergies, providing low invasiveness and safety. This study investigated the efficacy of percutaneous immunotherapy using hen egg lysozyme (HEL)-loaded PLGA-PEG-PLGA nanoparticles (NPs), as an antigen model protein derived from egg white, compared with that of HEL-loaded chitosan hydroxypropyltrimonium chloride (CS)-modified PLGA NPs used in previous research. The intradermal retention of HEL in excised mouse skin was measured using Franz cells, which revealed a 2.1-fold higher retention with PLGA-PEG-PLGA NPs than that with CS-modified PLGA NPs. Observation of skin penetration pathways using fluorescein-4-isothiocyanate (FITC)-labeled HEL demonstrated successful delivery of HEL deep into the hair follicles with PLGA-PEG-PLGA NPs. These findings suggest that after NPs delivery into the skin, PEG prevents protein adhesion and NPs aggregation, facilitating stable delivery deep into the skin. Subsequently, in vivo percutaneous administration experiments in mice, with concurrent iontophoresis, demonstrated a significant increase in serum IgG1 antibody production with PLGA-PEG-PLGA NPs compared with that with CS-PLGA NPs after eight weeks of administration. Furthermore, serum IgE production in each NP administration group significantly decreased compared with that by subcutaneous administration of HEL solution. These results suggest that the combination of PLGA-PEG-PLGA NPs and iontophoresis is an effective percutaneous immunotherapy for food allergies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641, Yamazaki, Noda 278-8510, Chiba, Japan.
- Modality Research Group, BioPharma Research Institute, Kaneka Corporation Inc., 1-8 Miyamae-cho, Takasago-cho, Takasago-shi 676-8688, Hyogo, Japan.
- Faculty of Pharmaceutical Sciences, Josai International University, 1 Gumyo, Togane 283-8555, Chiba, Japan.
- Department of Gastroenterology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku 216-8511, Kawasaki, Japan.
ORCID-Profile: Issei Takeuchi
Zitieren
APA
Sakurai, R., Iwata, H., Gotoh, M., Ogino, H., Takeuchi, I., Makino, K., Itoh, F., & Saitoh, A. (2024). Application of PLGA-PEG-PLGA Nanoparticles to Percutaneous Immunotherapy for Food Allergy. Molecules, 29(17), 4123. https://doi.org/10.3390/molecules29174123
Vancouver
Sakurai R, Iwata H, Gotoh M, Ogino H, Takeuchi I, Makino K, et al. Application of PLGA-PEG-PLGA Nanoparticles to Percutaneous Immunotherapy for Food Allergy. Molecules. 2024;29(17):4123. doi:10.3390/molecules29174123
BibTeX
@article{Sakurai2024,
author = {Sakurai, Ryuse and Iwata, Hanae and Gotoh, Masaki and Ogino, Hiroyuki and Takeuchi, Issei and Makino, Kimiko and Itoh, Fumio and Saitoh, Akiyoshi},
title = {Application of PLGA-PEG-PLGA Nanoparticles to Percutaneous Immunotherapy for Food Allergy},
journal = {Molecules},
year = {2024},
volume = {29},
number = {17},
pages = {4123},
doi = {10.3390/molecules29174123}
}
EUVIMED